SCOHIA PHARMA is a specialty bioventure with great expertise in the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases.
-
Publication
2023.06.12
Presentation of clinical data of SCO-240 at the 96th annual congress of Japan Endocrine Society: SSTR5 antagonist is a novel strategy to treat growth hormone-related disorders
-
Business
2023.02.22
SCOHIA PHARMA and Huadong Announce Global Expansion of the Strategic Collaboration for SCO-094
-
Business
2023.01.05
Issuance of Key Patent Covering Novel Nrf2 Activator
Page Top